Tyenne — Point32Health
Juvenile Idiopathic Arthritis
Preferred products
- Actemra
Initial criteria
- Documented diagnosis of polyarticular or systemic juvenile idiopathic arthritis
- Patient age ≥ 2 years
- Prescribed by or in consultation with a rheumatologist
- Documentation of one of the following: trial and failure of at least two medications from each of the following therapeutic categories (only one medication required if only one is available for that category): Janus Kinase Inhibitors (Rinvoq, Xeljanz); Selective T Cell Stimulators (Orencia); Tumor Necrosis Factors (Cimzia, Enbrel, Humira) OR contraindication to all Rinvoq, Xeljanz, Orencia, Cimzia, Enbrel, and Humira
- Documented previous failure of or clinical inappropriateness of treatment with Actemra